Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2024-06-17 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL BIOSCIENCES : publication scientifique de l'étude sur le mécanisme d'action de NFL-101 menée par le CEA dans ACS Chemical Neuroscience
Regulatory Filings Classification · 95% confidence The document is a press release from NFL BIOSCIENCES announcing the publication of a scientific article in a peer-reviewed journal (ACS Chemical Neuroscience) detailing the mechanism of action of their drug candidate, NFL-101. This is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement about scientific progress and publication, which often falls under general investor relations or regulatory news. Since the core content is the announcement of a scientific publication and its implications, and it doesn't fit the specific categories like 'Audit Report' (AR) or 'Management Reports' (MDA), the most appropriate classification is 'Regulatory Filings' (RNS) as a general regulatory/investor news announcement, or potentially 'LTR' if the scientific finding was related to a regulatory hurdle, but RNS is the best fit for general scientific progress announcements that are not formal financial reports.
2024-06-17 French
NFL BIOSCIENCES: Scientific publication of the study on the mechanism of action of NFL-101 conducted by the CEA in ACS Chemical Neuroscience
Regulatory Filings Classification · 95% confidence The document is a press release from NFL BIOSCIENCES announcing the publication of a scientific paper in a peer-reviewed journal (ACS Chemical Neuroscience) detailing the mechanism of action of their drug candidate, NFL-101. It discusses scientific findings, study details (CEA, mouse model, PET imaging), and future clinical trial expectations (CESTO 2). This content is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement related to scientific progress and intellectual property, which fits best under the general category of Investor Information or Regulatory Filings, as it is a specific, non-standard announcement. Given the options, it is a specific announcement about research findings, which is often disseminated via Regulatory Filings (RNS) if it doesn't fit the other specific categories (like DIV, CAP, MANG). Since it is a specific announcement about scientific progress and publication, and not a core financial report, RNS is the most appropriate fallback, although 'IP' (Investor Presentation) or 'LTR' (Legal/Regulatory) could be considered if the focus was on IP protection or regulatory hurdles, but here the focus is the publication itself. Given the nature of announcing a scientific publication, RNS (Regulatory Filings/General Announcement) is the best fit among the provided codes for this type of corporate update.
2024-06-17 English
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
AGM Information Classification · 99% confidence The document explicitly states it contains the 'RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024'. It details the resolutions voted upon, the participation rate, and the reappointments/departures of board members following the vote. This content directly corresponds to the outcome of a shareholder meeting, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the focus is on the *results* of the vote, not the presentation materials (AGM-R) or the proxy solicitation (PSI).
2024-05-31 English
NFL BIOSCIENCES : COMPTE RENDU DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 30 MAI 2024
AGM Information Classification · 99% confidence The document title explicitly states "COMPTE RENDU DE L'ASSEMBLEE GËNÉRALE MIXTE DU 30 MAI 2024" (Minutes/Report of the Combined General Meeting of May 30, 2024). The content details the voting results on various resolutions, including the renewal of board members, and confirms that the resolutions were approved. This directly corresponds to the documentation produced following an Annual General Meeting (AGM). Although it contains voting results (DVA), the primary nature of the document is the official record/minutes of the AGM itself, making AGM-R the most appropriate classification.
2024-05-31 French
NFL BIOSCIENCES : présentation des résultats de l'étude menée avec le CEA, au congrès de l'Albatros
Regulatory Filings Classification · 95% confidence The document is a press release from NFL BIOSCIENCES announcing that the results of a study on their drug candidate NFL-101, conducted with the CEA, will be presented at the Albatros congress on June 5, 2024. It details the study's findings, the background of the drug, and ongoing clinical trials. This is a general announcement regarding scientific/clinical progress and presentation of data, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is an announcement about scientific findings being presented at a conference, it best fits the category of general corporate or investor-related news that doesn't fit the highly specific categories. Given the options, 'Regulatory Filings' (RNS) serves as the best general announcement/press release fallback when specific categories like ER, IR, or CT do not apply, although 'Investor Presentation' (IP) is close, this is an announcement *about* a presentation, not the presentation itself. However, since it is a press release detailing scientific progress and upcoming presentation, and it is not a formal financial report, RNS is the most appropriate general classification.
2024-05-29 French
NFL BIOSCIENCES : Presentation of the study results conducted with the CEA at the Albatross congress
Regulatory Filings Classification · 90% confidence The document is an announcement by NFL BIOSCIENCES regarding the presentation of study results for their drug candidate NFL-101 at the Albatros congress. It details the study findings, the context of the presentation, and provides background information on the company and the drug. This type of communication, which announces scientific findings or corporate updates outside of mandatory financial filings (like 10-K or ER), fits best under a general 'Regulatory Filings' or 'Investor Presentation' category. Since it is specifically announcing scientific data presentation rather than a formal financial report or a general investor deck, and it is not a standard regulatory form, it is most closely aligned with providing information to investors about ongoing research and development. However, given the specific definitions, it is not a standard Investor Presentation (IP) which usually covers strategy/financials, nor is it a standard Earnings Release (ER) or Interim Report (IR). It is an announcement about scientific progress. Since it is a specific announcement about research results being presented, and it doesn't fit the other specific categories (like M&A, Capital, Dividend, etc.), the most appropriate general category for non-standard corporate updates that convey important operational/scientific news is Regulatory Filings (RNS), or potentially Investor Presentation (IP) if viewed as an update for the investment community. Given the focus on study results being presented at a conference, it functions as a specific corporate update. I will classify it as RNS as it is a specific, non-financial regulatory/corporate announcement that doesn't fit the other specialized codes.
2024-05-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.